OncLive Global

Dr. Polak on Evaluation of Cancer Genomes in Ghana Utilizing Liquid Biopsies

April 10th 2021

Paz Polak, PhD, discusses research that evaluated cancer genomes in Ghana through the use of liquid biopsies.

Daratumumab Consolidation Appears Safe, Shows Encouraging Efficacy in Very Good Responders With Myeloma

April 9th 2021

Daratumumab appears to be safe when used as consolidation therapy in patients with multiple myeloma, even soon after autologous stem cell transplant, and the agent has also demonstrated early efficacy in the setting of very good responders.

Dr. Ghidini on the Effects of Body Weight Loss in Gastric/GEJ Cancer

April 6th 2021

Michele Ghidini, MD, PhD, discusses the effects of body weight loss in gastric/gastroesophageal junction cancer.

Duvelisib Granted Positive EU Opinion for Relapsed/Refractory CLL and Refractory Follicular Lymphoma

April 1st 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of single-agent duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia following at least 2 prior therapies, and follicular lymphoma that is refractory to at least 2 prior systemic treatments.

Approval Sought for Plinabulin Plus G-CSF in United States and China for Prevention of CIN

April 1st 2021

A new drug application has been submitted to the FDA and the China National Medical Products Administration for the use of plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

Cabozantinib/Nivolumab Combo Approved in Europe for Advanced RCC

March 31st 2021

The European Commission has approved the combination of cabozantinib plus nivolumab for use as a frontline treatment in patients with advanced renal cell carcinoma.

Gilteritinib Succeeds in Chinese Confirmatory Trial for FLT3-Mutated AML

March 30th 2021

Gilteritinib was found to result in a significant improvement in overall survival when used in patients with FLT3-mutated, relapsed/refractory acute myeloid leukemia, meeting the primary end point of the confirmatory phase 3 COMMODORE trial in China.

EU Panel Recommends Updated Label for Pembrolizumab in Select Locally Advanced or Metastatic Urothelial Cancer

March 30th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion in favor of recommending that the label for pembrolizumab in Europe be updated to include findings from the phase 3 KEYNOTE-361 trial.

Enzalutamide Granted Positive EU Opinion for Metastatic Hormone-Sensitive Prostate Cancer

March 30th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend an additional indication of enzalutamide for the treatment of adult patients with metastatic hormone-sensitive prostate cancer.

Dr. Au on the Impact of COVID-19 on Cancer Care

March 29th 2021

Lewis Au, MBBS, BMedSci, FRACP, discusses the impact that COVID-19 has had and will continue to have on cancer care.

x